Search the Newsreel

ImageneBio (IMA) registers 1.37M existing shares for resale on Form S-3

ImageneBio, Inc. (IMA) has filed a Post-Effective Amendment No. 2 to convert its existing Form S-1 into a Form S-3 shelf registration, allowing for the resale of 1,371,224 shares of common stock. These shares originated from a July 25, 2025 PIPE Financing and are …

Earnings Flash (QGEN) QIAGEN N.V. Reports Q2 Revenue $535.0M, vs. FactSet Est of $527.5M

Earnings Flash (QGEN) QIAGEN N.V. Posts Q2 Adjusted EPS $0.62 per Share, vs. FactSet Est of $0.60

Qiagen meldet stagnierenden Q2-Umsatz und bestätigt Jahresprognose

QIAGEN übertrifft Prognose für das zweite Quartal 2026 dank solider Umsatzzuwächse seiner Wachstumsträger und bestätigt Jahresprognose

QIAGEN Exceeds Q2 2026 Outlook as Pillars Deliver Solid Sales Growth; Reaffirms Full-Year Outlook

Q2 2026 results: Net sales of $535 million unchanged compared with Q2 2025 on a reported basis and at constant exchange rates (CER), exceeding the outlook for an about 2% CER decline Growth pillars deliver about 5% CER growth, led by Sample technologies, QIAcuity …

CCORF Maintains Niagen Bioscience(NAGE.US) With Buy Rating, Maintains Target Price $10

CCORF has reiterated its Buy rating for Niagen Bioscience (NAGE.US) and maintained its target price at $10. This indicates a continued positive outlook from the firm regarding Niagen Bioscience's stock performance.

Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results

Niagen Bioscience, Inc. announced its Q2 2026 financial results, reporting net sales of $29.8 million and a net income of $1.0 million. The company also highlighted strategic advancements, including the launch of its Niagen Plus telehealth platform and the introduction of NB4168, a pharmaceutical …

Niagen Bioscience Inc (NAGE) (Q2 2026) Earnings Call Highlights: E-Commerce Surge and China ...

Niagen Bioscience Inc (NAGE) reported robust Q2 2026 results, driven by significant e-commerce growth, particularly on its TrueNiagen website and Amazon, and impressive expansion in the China cross-border market. The company is strategically diversifying into new high-growth verticals like skincare and IV/injection therapies, backed …

ImageneBio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Exagen Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:XGN) 2026-08-05

Exagen Inc. reported record quarterly revenue of $19.9 million in Q2 2026, driven by increased AVISE test volumes and improved pricing. The company raised its full-year 2026 revenue guidance to $72-$75 million and aims for sustainable adjusted EBITDA breakeven at around $80 million in …

MGX|Metagenomi Inc|Price:1.215|Chg%:+0.005

Metagenomi Inc (MGX) has a TradingKey Stock Score indicating stable fundamentals and significant growth potential, although its valuation is considered fairly valued within the Biotechnology & Medical Research industry. The company, focused on precision genetic medicine, has seen high institutional ownership and multiple "Buy" …

Niagen Bioscience, Inc. (NASDAQ:NAGE) Given Consensus Rating of "Buy" by Brokerages

Niagen Bioscience, Inc. (NASDAQ:NAGE) has received a consensus "Buy" rating from five brokerages, with an average 12-month price target of $10.33. Despite the positive analyst sentiment, the company's shares recently traded down to $3.06, near its 52-week low. Institutional investors hold a significant 15.41% …

The Agency Group Australia (ASX:AU1) Surges as First-Half Momentum Returns to Focus

Ultragenyx Pharmaceutical Q2 Loss Narrows as Revenue Rises; 2026 Revenue Guidance Reaffirmed

Ultragenyx Pharmaceutical Inc. reported a narrower Q2 loss and increased revenue, surpassing FactSet estimates for both metrics. The company also reaffirmed its 2026 revenue guidance. This positive financial performance comes as the biopharmaceutical company continues to develop and commercialize treatments for rare and ultra-rare …

Janus Henderson Group PLC Makes New Investment in Qiagen N.V. $QGEN

Janus Henderson Group PLC has made a new investment in Qiagen N.V., purchasing 366,661 shares valued at approximately $14.6 million, giving it a 0.18% stake. Other institutional investors have also adjusted their holdings, with institutional ownership of Qiagen reaching 70%. Analyst sentiment for Qiagen …

Ultragenyx Pharmaceutical Inc. Q2 2026: Revenue $214M, EPS $(0.90) — 10-Q Summary

Ultragenyx Pharmaceutical Inc. (RARE) reported Q2 2026 results with revenue of $214M, a net loss of $92M, and diluted EPS of $(0.90), showing year-over-year improvement. Revenue growth was driven by Crysvita sales and royalties, and expanded demand for Evkeeza. The company also advanced its …

Ultragenyx Pharmaceutical (NASDAQ: RARE) posts $214M Q2 revenue, eyes 2027 profit

Jullundur Motor Share Price Today, Jullundur Motor Stock Price Live NSE/BSE Updates

ImageneBio (Nasdaq: IMA) details Q2 2026 loss and $136M cash runway

Exagen (XGN) Stock Gets Fair Value Boost As Analysts Weigh Growth And Execution

Qiagen Aktie: Prognose übertroffen

Ultragenyx's Q2 Earnings Beat Estimates, Revenues Jump Y/Y

QIAGEN's growth pillars deliver 5% CER growth as U.S. testing falls

Toyota, Volkswagen, and Mazda sales are plunging in Australia as EVs and Chinese brands surge

Photo Credit: YouTube A rapid move toward electric vehicles is reshaping Australia's car market. Lower-cost Chinese models are attracting buyers who want more technology and better value. That change is putting some of the country's most established brands under strain, including Toyota, Volkswagen, and …

Ultragenyx Pharmaceutical Q2 2026 Earnings Call Transcript

Ultragenyx Pharmaceutical reported a record quarterly revenue of $214 million for Q2 2026, driven by strong performance across its commercial products Crysvita, DOJOLVI, Evkeeza, and MEPSEVII. The company is preparing for potential FDA decisions on its first two gene therapies, DTX-401 for GSDIa and …

Earnings call transcript: Niagen Bioscience posts q2 2026 growth, lifts spending

Niagen Bioscience (CDXC) reported Q2 2026 revenue of $29.8 million, driven by growth in its Tru Niagen supplement and e-commerce, but net income dropped to $1 million ($0.01 per diluted share) due to increased marketing and product development spending. The company is transitioning into …

The Agency Group Australia Securities Subject to Temporary Trading Pause

QIAGEN NV Revenue Breakdown – BIVA:QIA/N

QIAGEN NV (BIVA:QIA/N) generated 37.68 billion MXN in revenue last year. Its top-performing segment was Diagnostic Solutions, contributing 14.48 billion MXN. The United States was the largest regional contributor, accounting for 18.00 billion MXN of the total revenue.

Is Niagen Bioscience Inc (NAGE) Undervalued After Q2 Earnings Mi

Niagen Bioscience (NASDAQ:NAGE) Announces Quarterly Earnings Results, Meets Expectations

Niagen Bioscience (NASDAQ:NAGE) reported quarterly earnings of $0.01 EPS, which met analyst expectations. The company demonstrated a net margin of 14.29% and a return on equity of 22.68%. Despite the stock trading near its 52-week low, analysts maintain a generally positive "Buy" rating with …

Ultragenyx (RARE) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Ultragenyx (RARE) reported $214 million in revenue for the quarter ended June 2026, representing a year-over-year increase of 28.5%. EPS of -$0.90 for the same period compares to -$1.17 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $181.01 million, …

Ultragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimates

Ultragenyx Pharmaceutical Inc reports results for the quarter ended June 30 - Earnings Summary

Ultragenyx Pharmaceutical Inc has released its earnings summary for the quarter that ended on June 30. The article, sourced from Reuters and republished on TradingView News, provides details on the company's financial performance. To access the full report and more in-depth analysis, readers are …

BRIEF-Exagen Inc. Q2 Revenue USD 19.941 Million Vs. IBES Estimate USD 17.8 Million

Exagen Inc. reported its Q2 revenue at $19.941 million, surpassing the IBES estimate of $17.8 million. The brief financial update indicates a stronger-than-expected performance for the company in the second quarter.

Earnings Flash (RARE) Ultragenyx Pharmaceutical Posts Q2 Loss of $0.90 per Share, vs. FactSet Est $1.22 Loss